Media Release

REMUS PHARMACEUTICALS LIMITED REPORTS H1-FY26 CONSOLIDATED PROFIT AFTER TAX OF INR 17.50 CRORES WITH A 33.97 % GROWTH COMPARED TO H1-FY25

November 10, 2025: Remus Pharmaceuticals Limited (NSE-SME: REMUS) announces its results for the half year ended September 30, 2025

Consolidated Financial Performance:

H1 FY26 vs H1 FY25

Revenue From Operations	EBITDA	PAT
H1 FY26: 400.20 INR Cr	**H1 FY26: 26.91 INR Cr**	**H1 FY26[1]: 17.50 INR Cr**
H1 FY25: 272.61 INR Cr	**H1 FY25: 21.18 INR Cr**	**H1 FY25: 13.06 INR Cr**
Growth: 46.80% ↑	*Growth: 27.08%* ↑	*Growth: 33.97%* ↑

H1-FY26 Business Highlights:

- **Successful Tender Achievement – Nicaragua**
  Remus participated in the **Nicaragua national tender** and **successfully secured two key product awards**, strengthening its presence in the Central American region.

- **Introduction of a New Therapeutic Segment**
  Launched **Rivastigmine Patch** across multiple markets, marking Remus's expansion into a **new therapeutic category**.

- **Strong Market Performance – Bolivia (Private Market)**
  Relius Pharma SRL (Bolivian subsidiary of Remus) achieved successful **commercial launches** of the following key products:
  • Rivaroxaban 10 mg Tablet
  • Eltrombopag 25 mg Tablet
  • Carbidopa + Levodopa 250 mg + 25 mg Tablet
  • Cefepime 1 gm Injection

- **Regulatory Milestone – Myanmar**
  Secured **37 new product approvals** between **April to September 2025**, further strengthening Remus's regulatory footprint in the ASEAN region.

- **New Market Expansion – Algeria**
  Successfully **entered the Algerian market** and **initiated product registration activities**, opening new growth opportunities in North Africa.

- **Tender Participation – Mauritania & Kuwait**
  Participated in **national tenders with 20 products in each country**; reflecting Remus's ongoing efforts to broaden tender market reach.

Management Comments:

Commenting on the results, Mr. Arpit Deepakkumar Shah, Managing Director of Remus Pharmaceuticals Limited said, "*The Company has maintained the growth trajectory for the first half of the financial year and*

[1] *PAT before Minority* ***Interest for*** *H1 FY26 is 21.59 INR crores*

has met our expectations. The growth that we have achieved testifies the hard work and dedication of our team. Going forward we are looking to expand our reach to new markets and product segments. Our government institutional tenders and rigorous penetration in B2C markets will glorify our trajectory of a better second half of current financial year. We are confident that our strong and strategic performance will continue to drive our growth in the future."

Financial Statements:

Results for the half year ended September 30, 2025, prepared under Ind AS, are available in the Investors section of our website https://remuspharma.com/

About Remus Pharmaceuticals Limited:

Remus Pharmaceuticals Limited is engaged in exporting, marketing and distribution of finished formulations of pharmaceutical drugs. Having strong footprints in 40+ countries across the globe, Remus is involved in the sales of niche, specialized and critical care finished formulations. Remus is actively engaged in D2C via Pharmacy networks for specialty niche formulations through its subsidiaries in various markets.

Safe Harbor

This document includes certain forward-looking statements which are tentative, based on current expectations of the management of Remus Pharmaceuticals Limited or any of its subsidiaries ("Remus"). These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, and/or regulatory factors, exchange rate fluctuations, cash flow projections, interest, and other costs. Remus, its directors, and any of the affiliates or employees are under no obligation to and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise. Remus does not undertake any obligation to revise or update any forward-looking statement that may be made from time to time by or on behalf of the Company including to reflect actual results, changes in assumptions or changes in factors affecting these statements.

Follow Remus Pharmaceuticals Limited on LinkedIn: https://www.linkedin.com/company/remus-pharmaceuticals/

Contact Information:

Investor Relations Representative: Mr. Anuj Sonpal Valorem Advisors Tel: +91-22-4903-9500 Email: remus@valoremadvisors.com	**Chief Financial Officer** Ms. Anjali Shah Remus Pharmaceuticals Limited Email: ir@remuspharma.com